Efficacy of bevacizumab on brain radiation necrosis after irradiation for brain diseases.

Efficacy of bevacizumab on brain radiation necrosis after irradiation for brain diseases. - Efficacy of bevacizumab on radiation necrosis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024794

Enrollment

Registered

2016-11-11

Start date

2015-06-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain radiation necrosis

Interventions

Bevacizumab of 5mg/kg was administered every other week, 3 cycles in total.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients were suspected radiation necrosis on a basis of MRI and/or PET. Patients underwent brain irradiation for brain diseases. Patients had any symptoms.

Exclusion criteria

Exclusion criteria: Patients had hemorrhagic diseases. Patients had allergy for bevacizumab. Patients were suspected tumor recurrence. Pregnant patients.

Design outcomes

Primary

Measure	Time frame
duration of remission in brain edema	—

Secondary

Measure	Time frame
1) frequency and severity of adverse events related to short-scheduled bevacizumab 2) treatment efficacy of rechallenge of bevacizumab on radiation necrosis after relapse	—

Countries

Japan

Contacts

Public ContactMotomasa Furuse

Osaka Medical College Neurosurgery

neu054@osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026